Vinca alkaloids in combination with inhibitors of EGFR, ERBB2, MEK, for the treatment of mutant Ras-containing tumors.

The current disclosure relates to pharmaceutical combinations useful in the treatment of certain types of cancer. In particular the disclosure relates to the combined use of vinca alkaloid drugs with inhibitors of EGFR/ERB2 and inhibitors of MEK in a triple combination. Ian Bell ian.bell@oncode.nl +31628374976

September 8, 2019

Related Blog

Smart, interactive desk

May 8, 2023 No Comments

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Ultra-Cooled Autonomous Container (UAC) for the Transport and Storage of Goods

December 23, 2022 No Comments

Universitat Politècnica de València Background The current health emergency context has challenged technology in various industrial sectors. In particular, the recent manufacture

Mechanical Hamstring™

December 22, 2022 No Comments

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Vinca alkaloids in combination with inhibitors of EGFR, ERBB2, MEK, for the treatment of mutant Ras-containing tumors.

Related Blog

Smart, interactive desk

Ultra-Cooled Autonomous Container (UAC) for the Transport and Storage of Goods

Mechanical Hamstring™

Join Our Newsletter